Jean-François Le Bigot
Amministratore Delegato presso Oncovita
Profilo
Jean-François Le Bigot is currently the Chief Executive Officer at Oncovita SAS and the Chairman at Ginko Invest.
He was previously the Director at Affluent Medical SA from 2020 to 2022.
Posizioni attive di Jean-François Le Bigot
| Società | Posizione | Inizio |
|---|---|---|
Oncovita
 Oncovita BiotechnologyHealth Technology Oncovita SAS is a biotech company based in Paris, France. Oncovita is developing a virus-derived vaccine technology to treat multiple types of cancers. The technology utilizes the natural anti-cancer and immunogenic properties of a harmless vaccine, making it a versatile platform. The MeasovirTM platform, derived from the safe and highly immunogenic measles vaccine virus, has clinically proven oncolytic potential and specifically targets and destroys cancer cells. The French company was founded in 2015 by Frédéric Tangy and is currently led by CEO Jean-François Le Bigot. | Amministratore Delegato | - |
Ginko Invest
 Ginko Invest Financial ConglomeratesFinance Ginko Invest operates as an investment firm. | Presidente | - |
Precedenti posizioni note di Jean-François Le Bigot
| Società | Posizione | Fine |
|---|---|---|
| AFFLUENT MEDICAL | Direttore/Membro del Consiglio | 19/01/2022 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| AFFLUENT MEDICAL | Health Technology |
| Aziende private | 2 |
|---|---|
Ginko Invest
Ginko Invest Financial ConglomeratesFinance Ginko Invest operates as an investment firm. | Finance |
Oncovita
Oncovita BiotechnologyHealth Technology Oncovita SAS is a biotech company based in Paris, France. Oncovita is developing a virus-derived vaccine technology to treat multiple types of cancers. The technology utilizes the natural anti-cancer and immunogenic properties of a harmless vaccine, making it a versatile platform. The MeasovirTM platform, derived from the safe and highly immunogenic measles vaccine virus, has clinically proven oncolytic potential and specifically targets and destroys cancer cells. The French company was founded in 2015 by Frédéric Tangy and is currently led by CEO Jean-François Le Bigot. | Health Technology |
- Borsa valori
- Insiders
- Jean-François Le Bigot
